NEONEOGENOMICS INC
- BusinessWire
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
The collaboration is designed to support faster, more informed care for patients and providers NeoGenomics, Inc. (NASDAQ:NEO), a provider of oncology diagnostic solutions that enable precision medicine across the ...
- BusinessWire
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2026 financial results after the close of the ...
- Analyst Upgrades
StoneX Maintains Buy on NeoGenomics, Raises Price Target to $20
StoneX analyst Bruce D. Jackson maintains NeoGenomics with a Buy and raises the price target from $16 to $20. ...
- Analyst Upgrades
This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Analysts upgraded Boyd Gaming, NeoGenomics, PENN Entertainment, XP and Rezolute, raising targets for several names. ...
- Analyst Upgrades
Needham Maintains Buy on NeoGenomics, Raises Price Target to $22
Needham analyst Mike Matson maintains NeoGenomics with a Buy and raises the price target from $19 to $22. ...
- Analyst Upgrades
BTIG Upgrades NeoGenomics to Buy, Announces $28 Price Target
BTIG analyst Mark Massaro upgrades NeoGenomics from Neutral to Buy and announces $28 price target. ...
- BusinessWire
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
Warren Stone, current President and COO, to become CEO and a member of the Board effective January 4, 2027Tony Zook to remain CEO through January 3, 2027, and become Executive Chairman effective January 4, 2027Lynn ...
- Earnings Call Transcripts
NeoGenomics Laboratories, Inc. - 1773793 - NEOGENOMICS INC
Thank you everyone for joining us. It's my pleasure to introduce the Neogenomics team. We're glad to have you here at the Morgan Stanley Healthcare Conference this morning. I'm joined by Tony Zook, Chief Executive Office ...
- Earnings Call Transcripts
NeoGenomics Laboratories, Inc. - 1773793 - NEOGENOMICS INC
Thank you everyone for joining us. It's my pleasure to introduce the Neogenomics team. We're glad to have you here at the Morgan Stanley Healthcare Conference this morning. I'm joined by Tony Zook, Chief Executive Office ...
- BusinessWire
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that the Company will participate in the Morgan Stanley 24th Annual Global Healthcare ...
- BusinessWire
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic ...
- Analyst Upgrades
Needham Maintains Buy on NeoGenomics, Raises Price Target to $19
Needham analyst Mike Matson maintains NeoGenomics with a Buy and raises the price target from $15 to $19. ...
- Earnings Call Transcripts
NeoGenomics Second Quarter 2026 Earnings Call - NEOGENOMICS INC
Good afternoon, and welcome to the Neogenomics Second Quarter 2026 Financial Results Call. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. I will now ...
- BusinessWire
NeoGenomics Reports Second Quarter 2026 Results
Total revenue increased 11% YoY to $202 million Clinical services revenue grew 14%, with NGS revenue growth of 26% Company raises full-year 2026 revenue and adjusted EBITDA guidance NeoGenomics, Inc. (NASDAQ:NEO) ...
- Analyst Upgrades
Benchmark Maintains Buy on NeoGenomics, Raises Price Target to $16
Benchmark analyst Bruce D. Jackson maintains NeoGenomics with a Buy and raises the price target from $11 to $16. ...
- BusinessWire
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
NeoGenomics, Inc. (the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has finalized a civil settlement with the Department ...
- BusinessWire
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
Available within NEO PanTracer™ Pro for prostate cancer and as a standalone test, PTEN IHC CDx identifies patients who may be eligible for TRUQAP® NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology ...
- BusinessWire
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2026 financial results after the close of U.S. ...
- BusinessWire
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Carolyn Starrett to its Board of Directors. Ms. Starrett brings ...
- BusinessWire
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today the pricing of its previously announced private offering of $275 million aggregate ...
- BusinessWire
NeoGenomics to Present New Research at ASCO Annual Meeting 2026
Presentations highlight advances in MRD, precision oncology, and real-world evidence across solid tumors and hematologic malignancies NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions ...
- BusinessWire
NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: The 23rd Annual ...
- Analyst Upgrades
Benchmark Upgrades NeoGenomics to Buy, Announces $11 Price Target
Benchmark analyst Bruce Jackson upgrades NeoGenomics from Hold to Buy and announces $11 price target. ...
- Analyst Upgrades
TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $14
TD Cowen analyst Dan Brennan maintains NeoGenomics with a Buy and raises the price target from $13 to $14. ...
- Analyst Upgrades
Leerink Partners Upgrades NeoGenomics to Outperform, Raises Price Target to $25
Leerink Partners analyst Puneet Souda upgrades NeoGenomics from Market Perform to Outperform and raises the price target from $12 to $25. ...